Allen & Overy (A&O) client Pfizer has lost a landmark Supreme Court battle against a host of manufacturers, leaving it vulnerable to substantial financial claims.
In a judgment handed down yesterday (14 November), the Supreme Court upheld lower court decisions that Pfizer’s patent for its pregabalin pain relief product was invalid. Branded as ‘Lyrica’, the pregabalin-based drug is used to treat neuropathic pain as well as generalised anxiety disorder and epilepsy.
